ABS.PA (ABS.PA) News
Track canonical SquawkNews coverage tagged to ABS.PA, ABS.PA. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
AB Science expects to resume AB8939 Phase 1 in Q1 2027 and masitinib Phase 3 in Q4 2027
AB Science SA said it expects to resume AB8939 Phase 1 in Q1 2027 and masitinib Phase 3 in Q4 2027, revising its operating plan after a GCP inspection by France, Denmark and Greece authorities.
EARNINGS | Sep 29, 2026, 06:41 AM UTC
M
AB Science (ABS.PA) delays AML and ALS trial restarts after “for cause” GCP inspection
AB Science revised its development plan after a “for cause” sponsor Good Clinical Practice inspection by French, Danish and Greek authorities. The Phase 1 AB8939 AML trial is targeted to resume in Q1 2027, and the masiti
EARNINGS | Sep 29, 2026, 06:10 AM UTC